Abstract. Transarterial embolization (TAE) is a palliative option commonly used for the treatment of advanced, unresectable hepatocellular carcinoma (HCC). However, patient prognosis in regards to overall survival has not improved with this method, mainly due to hypoxia-inducible factor-1α (HIF-1α)-induced angiogenesis and invasiveness. Thus, it is hypothesized that HIF-1α may be an ideal knockout target for the treatment of HCC in combination with TAE. Thus, in the present study, HIF-1α knockout was conducted in human liver cancer SMMC-7721 cells and a xenograft HCC model was established using a lentivirus-mediated CRISPR/Cas system (LV-Cas) with small guide RNA-721 (LV-H721). Furthermore, hepatic artery ligation (HAL) was used to mimic human transarterial chemoembolization in mice. The results revealed that HIF-1α was highly expressed in both HCC patient tissues and SMMC-7721-induced tumor tissues. The HIF-1α knockout in SMMC-7721 cells significantly suppressed cell invasiveness and migration, and induced cell apoptosis under CoCl2-mimicking hypoxic conditions. Compared with the control groups, HAL + LV-H721 inhibited SMMC-7721 tumor growth in orthotopic HCC and markedly prolonged the survival of HCC-bearing mice, which was accompanied by a lower CD31 expression (tumor angiogenesis) and increased apoptosis in the tumor cells. These findings demonstrated a valuable antitumor synergism in combining CRISPR/Cas9-mediated HIF-1α knockout with TAE in mice and highlighted the possibility that HIF-1α may be an effective therapeutic knockout target in combination with TAE for HCC treatment.

Introduction

As the fifth common human malignancy, hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated mortality worldwide (1). Traditional therapeutic strategies, including surgery, are often ineffective in controlling HCC or prolonged HCC-associated survival, partially due to late diagnoses (2,3). Transarterial embolization (TAE), including transarterial chemoembolization (TACE), is a common therapeutic strategy for patients with stage B HCC who are unable to undergo surgical resection (4). During TAE/TACE, an emulsion of materials that includes chemotherapeutic drugs is injected into the tumor-feeding arteries, thereby blocking the blood supply to the tumor, leading to ischemia, hypoxia and necrosis of the tumor tissues (5). Studies have indicated that TAE/TACE is effective in controlling HCC (6). However, tumor recurrence and poor prognosis frequently occur subsequent to TAE/TACE. Although significant
advances have been achieved in the treatment of HCC, such as gene therapy and immunotherapy (7-10), these strategies for patients are currently limited in use due to the high cost and time-consuming nature. Therefore, the current therapies, such as TAE, in combination with other novel technologies against HCC may be an affordable and feasible approach.

Precise gene knockout technology for editing the human genome has been applied to translational medicine, and the CRISPR/Cas9 (also known as clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) system is one of the outstanding methods (11). CRISPR/Cas9 is a bacterial system with endonucleases involved in adaptive immunity. The system can effectively target intended genomic loci by a small guide RNA (sgRNA), which is composed of a target complementary CRISPR RNA (crRNA) and an auxiliary trans-activating crRNA (tracrRNA) (12). Technologically, through a delivery vector, such as a lentiviral vector, designed sgRNAs and CRISPR/Cas9 can be expressed in a certain cell. When the CRISPR/Cas9 endonuclease targets a specific genomic locus through base pairing between the crRNA sequence and the target DNA sequence, a double-stranded DNA break is formed, and a targeted gene modification is achieved, causing gene disruption, which is much more efficient than the effect of other nucleases, such as Zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) (13). In addition, Genetic landscape and biomarkers of HCC have a clear delineation (14). Therefore, the CRISPR/Cas9 system, as a powerful gene-editing tool, is promising in the preclinical and clinical treatment of HCC, which is mainly caused by genetic mutations and an abnormally high expression of key oncogenic proteins.

Hypoxia inducible-factor-1α (HIF-1α), a hypoxia-induced oxygen-dependent transcription factor, play a vital role in the aggressiveness, angiogenesis and chemotherapy resistance of HCC, as well as in the maintenance of liver cancer stem cells (15). Particularly, HIF-1α activates the hypoxic pathways, leading to the overexpression of vascular endothelial growth factor (VEGF), triggering epithelial mesenchymal transition, tumor invasiveness and metastasis by promoting the expression levels of matrix metalloproteinase 2 (MMP2) and MMP9 (16,17). Our previous study demonstrated that HIF-1α was upregulated in HCC, and was associated with hepatic capsular invasiveness and portal vein metastasis (18). Additionally, the expression of multi-drug resistance protein (MDR) is also under the control of HIF-1α, and its protein product P-glycoprotein (P-gp) is capable of transporting chemotherapeutic drugs out of cells. Tumor cells with an excessive expression of P-gp are generally resistant to chemotherapeutic drugs (19). Notably, it has been reported that TAE/TACE induced liver hypoxia, and that the expression levels of HIF-1α in the serum and HCC tissues were significantly higher in patients who underwent TACE compared with those in the control group (20). High recurrence rates and metastases of HCC following TACE treatment are also involved in the HIF-1α-associated drug-resistance and hypoxia-tolerance (21). Thus, the inhibition of HIF-1α in combination with TAE may be a promising therapeutic approach against HCC.

In the present study, a lentivirus-mediated CRISPR/Cas9 system targeting the human HIF-1α gene was used to analyze the role of HIF-1α in the human liver cancer cell line SMMC-7721. The lentivirus-mediated HIF-1α disruption suppressed cell proliferation, migration and invasiveness, and induced apoptosis under CoCl2-induced hypoxic conditions. HIF-1α disruption also significantly inhibited SMMC-7721 xenograft tumor growth in the liver and prolonged the survival of HCC-bearing mice treated with hepatic artery ligation (HAL). These findings suggested that CRISPR/Cas9-based HIF-1α disruption improved the antitumor efficacy of HAL and further highlighted the possibility that HIF-1α may be an ideal knockout target for the treatment of HCC in combination with TAE.

Materials and methods

HCC patient data and tissue specimens. A total of 20 matched pairs of HCC and normal adjacent liver tissues were acquired during surgery between May 2014 and April 2016 at the Shenzhen People's Hospital (Shenzhen, China). Patients met the following criteria according to our previous work: i) male/female patient ratio was 1:1, patients ranged in age from 35 to 75 years; ii) HCC patients were newly diagnosed with liver function tests of Child-Pugh grade A; iii) without history of anticancer therapy; iv) without any distant metastasis; v) without other types of malignant tumors, autoimmune, liver disease or serious heart, lung, kidney, or blood disease; and vi) seronegative for hepatitis B surface antigen and HCV. The samples were either snap-frozen or stored in liquid nitrogen for protein extraction or fixed in formalin and embedded in paraffin for immunohistochemistry analysis.

Construction of the pLenti-CAS9-sgRNA vectors. sgRNAs were designed using the Optimized CRISPR Design tool (http://crispr.mit.edu/) as follows: sgRNA719, 5'-CCTCACACGCAAATAGCTGA-3'; sgRNA720, 5'-TACATCATTGTACCATG-3'; and sgRNA721, 5'-GTATGTTCTCACAGATGA-3'. LV-Ctrl was constructed as control lentiviruses that did not have any sgRNAs used for targeting the HIF-1α gene. The cDNAs encoding the sgRNAs for 3 gene knockout sites in the first exon of the HIF-1α gene were synthesized and purified (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Different programmed lentiviral plasmids based on the pLenti-CAS9-sgRNA-egfp (GeneChem Co., Ltd., Shanghai, China) were constructed as previously described (22).

Packaging and purification of the modified CRISPR/Cas9 lentiviruses. The CRISPR/Cas9 lentivirus production was performed following previously described protocols (22). Briefly, 12 145-mm Petri dishes were prepared and 1x10⁷ HEK293T cells [American Type Culture Collection (ATCC) Manassas, VA, USA] were seeded in each dish with Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.), containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), pLenti-CAS9-sgRNA-egfp (20 μg), psPAX2 (15 μg; Addgene, Inc., Cambridge, MA, USA), pMD2.G plasmid (10 μg; Addgene, Inc., Cambridge, MA, USA) and linear PEImax (Polysciences, Inc., Warrington, PA, USA) were mixed and added to the HEK293T cells in each dish. After 6 h of incubation in a CO₂ incubator at 37°C, the medium was replaced with complete medium. After 48 h, the cell supernatants were filtered through a 0.45-μm filter.

LIU et al: HIF-1α KNOCKOUT AND TAE IN HCC TREATMENT

2548
(EMD Millipore, Billerica, MA, USA). Subsequently, supernatants were ultracentrifuged (Beckman Coulter, Inc., Brea, CA, USA) at 20,000 x g for 2 h at 4°C, and the lentiviruses were suspended in PBS and stored at -80°C.

**Lentivirus infection in SMMC-7721 cells and the T7 endonuclease 1 assay (T7EI)** of HIF-1α-knockout. The titers of the concentrated lentiviruses was determined by a quantitative polymerase chain reaction (qPCR) method as described previously with 293T cells (23). Subsequently, SMMC-7721 cells (ATCC) were cultured in Dulbecco's modified Eagle's medium ( Gibco; Thermo Fisher Scientific, Inc.) with 10% FBS and 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in a CO2 incubator at 37°C. SMMC-7721 cells were infected with the lentivirus at a multiplicity of infection (MOI) of 2.5. To check the total percentage of GFP-positive cells, single-cell suspensions were prepared in PBS plus 2% FBS from trypsinized cells at 72 h after infection. After resuspension, cells were subjected to fluorescence activated cell sorting (FACS) analysis with a BD Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA) as described (22). Next, SMMC-7721 cell genomic DNA was extracted using a DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany). A mismatch-sensitive T7E1 assay kit (New England BioLabs, Inc., Ipswich, MA, USA) was then used to confirm CRISPR/Cas9 cleavage and targeted sequence disruption, according to the manufacturer's protocol. Subsequently, the PCR fragments containing each knockout gene locus were cloned with primers in different group using a Takara PCR amplification kit (cat. no. DR011; Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocols. The following primers was used: i) LV-H719 + 7721 cells group: 5'-ACA TGA AAG CAC AGA and 5'-CAA AAT CAA AAC ATT GCG ACC AC-3' (reverse); The SMMC-7721 cell line where cloned DNA sequences were then inserted into a plasmid using and 5'-CTT ACC ATT TCT GTG TGT AAG C-3' (reverse). The H721, 5'-TCT AAT CCT TCT GTG ATA AGC AG-3' (forward) sequence disruption, according to the manufacturer's protocol. Primers used in this experiment were as follows: **vegf** (reverse); β-actin, 5'-GTC CAC CGG AAATGCTTC TA-3' (forward) and 5'-TGC TG CTACC TTCCACGGCTTC-3' (reverse); and gfp, 5'-TGTT AGC GCTG CTACCC-3' (forward) and 5'-AGT AAC CTTG GAGTC GCTTC-3' (reverse).

**Protein sample preparation and western blotting.** Protein samples from patient tissues and SMMC-7721 cells were prepared using radio-immunoprecipitation assay lysis buffer (RIPA; Beyotime Institute of Biotechnology, China), and the protein concentration was detected by the BCA protein quantitation kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Western blot analysis was then performed based on protocols reported in a previous study (22). The following primary and secondary antibodies were used: Anti-VEGF (cat. no. 19003-1-AP; 1:2,000, ProteinTech, Inc., Chicago, IL, USA), anti-MDR1 (cat. no. PA5-28810; 1:2,000, Thermo Fisher Scientific, Inc.), anti-HIF-1α (cat. no. 20960-1-AP; 1:2,000, ProteinTech, Inc.), anti-β-actin (cat. no. MA1-140; 1:2,000, Thermo Fisher Scientific, Inc.), horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (cat. no. 7074; 1:2,000, Cell Signaling Technology, Inc., Danvers, MA, USA) and HRP-conjugated anti-mouse IgG (cat. no. 7076; 1:2,000, Cell Signaling Technology, Inc.) antibodies.

**MTT assay, apoptosis and cell cycle detection.** SMMC-7721 cells were cultured in 96-well (104 cells per well) or 6-well (3x105 cells per well) plates. A total of 150 μM cobalt chloride (CoCl2; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), a well-known hypoxia mimetic (24,25), was used to mimic tumor hypoxic conditions. In order to examine the cell proliferation, at 8 h after the lentivirus infection, 20 μl MTT (5 mg/ml) was added to each sample and incubated for 3 h. The formazan crystals were dissolved in dimethyl sulfoxide (150 μl/well), and the absorbance of each sample at 490 nm was measured.

For cell apoptosis analysis, a PE-Annexin V Apoptosis Detection kit (cat. no. 559763; BD Biosciences) was used. Briefly, 5 μl of Annexin V-PE and 5 μl of 7-AAD were added to 100 μl cell suspension with 1x binding buffer plus 5% FBS, and incubated for 15 min in the dark. Finally, cells were washed twice and diluted with buffer and immediately subjected to FACS analysis (22). For the detection of cell cycle progression, PI-RNase solution (cat. no. 550825; BD Biosciences) was used, according to the manufacturer's protocol. Flow cytometry was then performed using a BD FACS Aria flow cytometer (BD Biosciences), and the results were analyzed with FlowJo software (Tree Star, Inc., Ashland, OR, USA).

**Transwell and scratch wound assay.** A Transwell system with a 6.5-mm diameter and an 8.0 μm pore polycarbonate filter membrane (Corning Inc., Corning, NY, USA) was used, and Matrigel (cat. no. 356234; Corning Inc.) was used to form a thin gel layer on the wells. At 12 h after infection, the SMMC-7721 cells (1x105 per well) were added to the upper chamber. In the lower chambers, 20% FBS was added as a chemoattractant. CoCl2 (150 μM) was added to simulate hypoxia in both upper and lower chambers. After 24 h, the cells that had penetrated to the lower surface of the filter were stained with crystal violet and counted using a Nikon microscope (Nikon Corporation, Tokyo, Japan).
A scratch wound assay was also performed. Briefly, the SMMC-7721 cells were seeded into 6-well plates (3x10⁵ per well). Following infection with lentivirus after 12 h, a linear wound was created in the monolayer with a sterile 100-µl plastic pipette tip, and cells were then gently washed with PBS immediately. Cells were cultured under the CoCl₂-simulated hypoxic conditions and then observed under the microscope.

Establishment of SMMC-7721-Fluc cells. The overlapping gene mFluc2, which included the mCherry fluorophore and Fluc2 gene (the gene that expresses the firefly luciferase protein), was cloned from the pmCherry-C1 (Clontech Laboratories, Inc., Mountainview, CA, USA) and pGL4.17 plasmids (Promega Corp., Madison, WI, USA) using a Takara PCR amplification kit. The PCR cycling conditions were set as follows: 1 min at 95°C for denaturation, 45 cycles of 95°C for 30 sec, and 55°C for 30 sec, then 72°C for 1 min. Lastly 1 h at 4°C. Next, the pWPX-lmd-fluc2 plasmid was constructed, and the LV-mFluc lentivirus was packaged according to previous methods (22). The SMMC-7721 cells were infected with LV-mFluc with an MOI of 2.5, and the mCherry-positive SMMC-7721 cells were purified by flow cytometry (BD FACS Aria device) and cloned. Subsequently, a dual-luciferase reporter assay in the intended SMMC-7721-Fluc cells was conducted using the Dual-Luciferase® Reporter Assay system according to the manufacturer’s protocol (cat. no. E1910; Promega Corp., Madison, CA, USA). The primers used in this experiment are as follows: Clone for mcherry gene: 5'-GGGGATCCACGCGGCGAGGAGA-3’ (forward) and 5'-TCTTTATGTTTGGGCGTCCATCTTGACGTCGTCCATGCGCCGCG-3’ (reverse); and clone for Fluc gene, 5'-CGCGGCGAGGACGGGGAATGGAAGCAGAAGTGGGGAAGCGCAGAACTAACATGACG-3’ (forward) and 5'-ACGGGACTCTAGGTCCAGGAGTTCGATGATGAGAGGGCCAGG-3’ (reverse).

Animals and CRISPR/Cas9 treatment in vivo. Seventy male BALB/c nu/nu mice (4-6 weeks old, 16-20 g) were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd. (license no. SCXK (HU) 2007-0003; Shanghai, China). Mice were housed in specific pathogen-free (SPF) conditions, with a 12-hours light cycle and food and water ad libitum. In order to establish a subcutaneous HCC model, 4x10⁶ SMMC-7721 cells were injected in the right flank of the mouse subcutaneously (n=4/group). After 9 days, 5x10⁷ LV-H721, which was a lentivirus-mediated CRISPR/Cas system with small guide RNA-721, were injected into the tumor tissues. Tumor tissues injected with PBS or LV-Ctrl (a lentivirus without CRISPR/Cas system targeting HIF-1α) were used as control groups. The tumors were harvested 3 days post LV-infection for immunohistochemical examination.

The procedure for the establishment of the orthotopic liver tumor model was conducted according to a previously described method (26). Briefly, pentobarbital was dissolved in saline to obtain a 10 mg/ml solution. Mice were anesthetized with pentobarbital (50 mg/kg) through intraperitoneal injection and placed in a supine position. A small transverse incision was made below the sternum to expose the liver. A total of 5x10⁶ control lentivirus-infected SMMC-7721-Fluc cells (7721) or LV-H721-infected SMMC-7721-Fluc cells at 48 h after infection were suspended in 50 µl PBS and slowly injected into each mouse liver. At 5 days after implantation, mice were subdivided into four groups as follows: i) 7721-induced HCC + sham surgery (Ctrl; n=8); ii) 7721-induced HCC + HAL surgery (n=8); iii) control lentivirus-infected 7721-induced HCC + HAL (HAL+LV-Ctrl; n=8); and iv) LV-H721-infected 7721-induced HCC + HAL (HAL+LV-H721; n=8). HAL was performed in the mice by ligating the main branch of the hepatic artery. The tumor volume was measured by bioluminescence imaging with 200 µl D-luciferin potassium salt solutions (15 mg/ml; Sigma-Aldrich; Merck KGaA) after HAL during 2 weeks. After 2 weeks, the mice (n=5/group) were sacrificed and mouse tumor samples were collected for immunohistochemistry analysis. Furthermore, an extended observation of tumor-bearing mice with four different treatments was carried out again, and the mouse overall survivals were recorded.

Immunohistochemical staining for HIF-1α and CD31 expression in tissues. Human or SMMC-7721-induced mouse tumor tissues were fixed with 4% neutral paraformaldehyde. Next, the paraffin-embedded sections (human and mouse tumor tissues) were incubated with the anti-HIF-1α antibody (cat. no. 20960-I-AP; 1:100; ProteinTech, Inc., Rosemont, IL, USA) overnight at 4°C, followed by incubation with 50-100 µl 1x the secondary antibody solution for 1-h (cat. no. KHC-5, 1:1, ProteinTech, Inc.). The signals were detected by staining the sections with 3,3’-diaminobenzidine (DAB; ProteinTech, Inc.) and hematoxylin. Furthermore, to monitor the microvascular density (MVD), the mouse tumor tissues were stained with an anti-CD31 monoclonal antibody overnight at 4°C (cat. no. 14-0319-80; 1:300, Thermo Fisher Scientific, Inc.), and the rest of the test was carried out as previously described.

TUNEL staining assay for cell apoptosis in vivo. The DeadEnd™ Colorimetric TUNEL System (cat. no. G7130, Promega Corp.) was used for the TUNEL staining assay. Briefly, the tumor slides were incubated with terminal deoxynucleotidyl transferase (TdT) and a biotinylated nucleotide mixture at 37°C for 30 min. Subsequently, the endogenous peroxidases was blocked by immersing the slides in 0.3% hydrogen peroxide in PBS for 3-5 min at room temperature. The slides were incubated with streptavidin-HRP and visualized with DAB. Negative controls were set up by substituting distilled water for TdT in the working solution. The results are presented as the ratio of the TUNEL-positive cells to the total number of cells.

Statistics analysis. The statistical analysis was performed with SPSS version 17.0 software (SPSS, Inc., Chicago, IL, USA). All the data were analyzed using one-way analysis of variance followed by least significant difference post-hoc analysis, or using an unpaired two-tailed Student’s t-test (as appropriate). The survival curves were obtained by Kaplan-Meier analysis, and the prognostic significance was analyzed by the log-rank test. Statistically significant differences were denoted by P<0.05. All data were acquired from four repeated experiments.

Results

HIF-1α is overexpressed in human HCC tissues and in SMMC-7721-induced HCC xenograft tissues in mice. The
expression levels of HIF-1α protein were first analyzed in 20 paired HCC and normal adjacent liver tissues by western blot and immunohistochemical analyses. As shown in Fig. 1A and B, the HIF-1α protein levels in the HCC tissues were higher in comparison with those in the normal adjacent liver tissues, and the difference was found to be statistically significant (P<0.05; Fig. 1C).

SMCC-7721 cells, a human liver cancer cell line, were also used to establish an HCC model in BALB/c nu/nu mice. The results revealed that the implanted HCC cells had a significantly higher expression of HIF-1α protein as compared with the control groups (Fig. 2A). Subsequently, the SMCC-7721-induced HCC model was used in further CRISPR/Cas9-mediated HIF-1α-knockout experiments.
**HIF-1α-knockout via CRISPR/Cas9 suppressed HIF-1α expression.** To identify sgRNAs specifically targeting the gene loci of HIF-1α, three sgRNAs were designed to target the first exon of HIF-1α according to guidelines of the Optimized CRISPR Design online tool (Fig. 2B). The pLenti-CAS9-sgRNA719/720/721-egfp plasmids, based on the pLenti-CAS9 vector, were established (Fig. 2B). The CRISPR/Cas9 lentiviruses with different sgRNAs were labeled as LV-H719, LV-H720 and LV-H721. Subsequently, SMMC-7721 cells were infected with the lentiviruses at an MOI of 2.5, and the gene disruption efficacies were assessed, followed by the T7E1 endonuclease assay and DNA sequencing. The results demonstrated that all three sgRNAs led to DNA frameshift mutations and had high gene disruption efficiencies (Fig. 2C).

Furthermore, the results of the western blot analysis revealed that LV-H721 infection significantly reduced the expression of HIF1-α with the maximum efficiency (Fig. 2D). The percentage of total GFP-positive cells in LV-H721-infected SMMC-7721 cells was also measured to assess the lentiviral transfection efficiency, and was found to be 93.6% (Fig. 2E).

LV-Ctrl (a lentivirus without CRISPR/Cas system targeting HIF-1α) could also express GFP in the infected SMMC-7721 cells and had equal lentiviral transfection. It was observed that HIF-1α knockout caused by LV-H721 transfection in the cells was observed to significantly downregulate the mRNA levels of vegf and mdr1 as compared with those in the control groups (all P<0.001; Fig. 2F). As shown in Fig. 2G, the expression levels of the VEGF and MDR1 protein, which has been reported to be under the control of HIF-1α (17), were also inhibited in the present study. Thus, LV-H721 was used as a CRISPR/Cas9-mediated vector for further experiments.

The efficiency of LV-H721-mediated HIF-1α knockout was also examined in the mice. The SMMC-7721 xenograft HCC tissues were harvested 3 days post LV infection. Immunohistochemical examination revealed that HIF-1α was highly expressed in the control and LV-Ctrl-treated HCC tissues. Furthermore, the expression of HIF-1α was significantly reduced in the LV-H721-treated tissues when compared with those in the control groups (both P<0.001; Fig. 2A). Collectively, these data indicated that the lentivirus-mediated CRISPR/Cas9 efficiently disrupted the expression levels of HIF-1α gene and its targets, including VEGF and MDR1, in liver cancer cells and xenograft tumor tissues.

**HIF-1α knockout impairs cell invasion and migration.** First, the effect of the CRISPR/Cas9 based HIF-1α knockout on migration and invasion was determined in the SMMC-7721 cells (7721-HIF-1α-KO). The SMMC-7721 cells were infected with the lentiviruses, and CoCl2, a well-known hypoxia mimetic, was used to simulate the hypoxic conditions in vitro. In the transwell invasion assay, the number of invasive 7721-HIF-1α-KO cells that penetrated the polycarbonate filter was significantly reduced, and this difference was statistically significant (both P<0.001; Fig. 3A). Meanwhile, 7721-HIF-1α-KO cells exhibited further reduced relative migration rates at 24 and 48 h
post LV infection compared with the control groups in the scratch-wound assay, and the difference was statistically significant (all \( P<0.001 \); Fig. 3B). These results suggested that the disruption of HIF-1\( \alpha \) with the CRISPR/Cas9 system, particularly under the hypoxic microenvironment, inhibited liver cancer cell migration and invasion.

HIF-1\( \alpha \) disruption suppresses cell proliferation and induces cell apoptosis. Hypoxic conditions are reported in the majority of advanced HCC tissues, in particular in patients who undergo TAE. Therefore, the growth characteristics of the 7721-HIF-1\( \alpha \)-KO cells under the hypoxic microenvironment were analyzed using an MTT assay. The optical density, an indicator of the number of viable cells, was monitored subsequent to infection, and a growth curve was plotted (Fig. 4A). The results demonstrated that cell proliferation was profoundly suppressed at 48 and 96 h post infection between the LV-H721-treated group and the control groups (all \( P<0.001 \)).

Subsequently, the cell cycle progression under hypoxic conditions was assessed at 48 h post infection in vitro. SMMC-7721 cells infected with LV-Ctrl and LV-H721 exhibited marked changes in their cell cycle progression, and there was an ~10% decrease in the number of cells in the G0/G1-phase, as well as a concomitant increase in the G2/M-phase (Fig. 4B). However, the S-phase ratio, serving as the marker of cell division, was almost consistent. These data suggested that HIF-1\( \alpha \) knockout did not induce evident cell cycle arrest (Fig. 4B and C). Furthermore, HIF-1\( \alpha \) knockout led to a high percentage of early cell apoptosis under hypoxic conditions, and the rates of cell apoptosis were 7.5% at 24 h and 28.6% at 48 h post infection, with a statistically significant difference observed (\( P<0.001 \); Fig. 4D). These results suggested that disruption of HIF-1\( \alpha \) by the CRISPR/Cas9 system inhibited cell proliferation and induced cell apoptosis in the SMMC-7721 cells.

**Figure 4.** Hypoxia inducible factor-1\( \alpha \) knockout leads to a reduced cell proliferation rate and increased apoptosis in the SMMC-7721 cells. Cells were infected with LV-Ctrl and LV-H721 under hypoxic conditions. (A) MTT assay showing the cell growth characteristics following lentivirus infection for 4 days. Statistically significant differences were denoted between CoCl\( \mathrm{2} \)+LV-H721 group and the other three groups correspondingly (Ctrl, CoCl\( \mathrm{2} \)+Ctrl, and CoCl\( \mathrm{2} \)+LV-Ctrl groups, all \(^{***}P<0.001\)). (B) Cell cycle distribution and (C) percentage of cells in G0/G1 stage in each group, as determined by flow cytometry analysis under CoCl\( \mathrm{2} \)-mimicking hypoxic conditions at 48 h post infection in vitro. (D) Flow cytometry analysis of cell apoptosis under hypoxic conditions at 24 and 48 h post infection. Bar graphs show the mean percentage ± standard deviation of the cell ratios. \(^{**}P<0.01\) and \(^{***}P<0.001\). Ctrl, control; LV, lentivirus.

CRISPR/Cas9-mediated HIF-1\( \alpha \) disruption with HAL inhibits liver tumor growth. The SMMC-772-Fluc cells were established and cloned (data not shown). On days 5, 10, 15 and 20 after implantation of these cells into the mice, the tumor volume was measured by bioluminescence imaging (Fig. 5A). On day 20, the representative features of the tumors in mice with live bioluminescence imaging are shown in Fig. 5B and tumor outlines in mouse livers are shown in Fig. 5C. The results demonstrated that HAL inhibited the progression of HCC when compared with that observed in the control group (\( P<0.05 \); Fig. 5A). Notably, the combination of HAL and LV-H721 exhibited a more significant anti-tumor effect on day 20 as compared with that in the control, HAL and HAL + LV-Ctrl groups (\( P<0.001 \), \( P<0.05 \) and \( P<0.05 \), respectively; Fig. 5A). Furthermore, the overall median survival results revealed that the combination of HAL + LV-H721 significantly prolonged the survival of tumor-bearing mice from ~40 to 60 days, as compared with the other groups (\( P<0.05 \); Fig. 5D), indicating that HIF-1\( \alpha \) disruption enhanced the efficacy of HAL in the treatment of HCC.
Combination of the CRISPR/Cas9-mediated HIF-1α disruption with HAL inhibits angiogenesis and induces apoptosis in tumor tissues. The expression of CD31 was used as a marker of vascular endothelial cells, or tumor microvascular density (MVD). From immunohistochemical analysis of CD31 protein expression (Fig. 6A), the CD31 was significantly higher in the mice treated with HAL and HAL+ LV-Ctrl as compared with the control group, whereas CD31 was significantly lower in the combined HAL+LV-H721 treatment group in comparison with the HAL and HAL+ LV-Ctrl groups (all P<0.05; Fig. 6B). A TUNEL assay was also performed to detect the apoptotic cells in the tumor tissues. The results demonstrated that combined treatment with HAL+LV-H721 significantly enhanced cell apoptosis compared with that observed in the control, HAL and HAL+LV-Ctrl groups (P<0.01, P<0.05 and P<0.05, respectively; Fig. 6C and D). Collectively, these results indicated that HAL treatment may promote the microvascular growth. However, HIF-1α knockout in tumor tissues significantly inhibited the tumor hypoxia-mediated increase in CD31 expression and the microvascular growth, while it promoted tumor cell apoptosis in vivo. These results further highlight the relevance of HIF-1α inhibition in combination with HAL in the treatment of advanced, unresectable HCC.

Discussion

TAE, including TACE, is one of the most important treatment strategies for advanced HCC; however, these methods have various side effects. TAE has been suggested to aggravate the hypoxia condition of solid tumors and inevitably activate various pathways that promote cell invasion, tumor metastasis and angiogenesis (27,28). Previously, Hanahan and Weinberg (29) proposed ten hallmarks of cancer and therapeutic targets for these hallmarks. In the present study, HIF-1α was proposed as a potentially effective therapeutic knockout target of the hallmarks of HCC during TAE. The results demonstrated that HIF-1α knockout in SMMC-7721 cells significantly suppressed cell invasiveness and migration, and induced cell apoptosis under CoCl2-simulated hypoxic conditions. Hepatic artery ligation (HAL) was used to mimic human transarterial chemoembolization in mice. Results showed that the combination method of HAL and Cas9-mediated genome editing exhibited an anti-tumor effect in an orthotopic HCC model, as well as prolonged the survival of tumor-bearing mice. The current preclinical study indicates that the combination of HAL and HIF-1α knockout may have a huge potential for further clinical applications.
Enhanced tumor invasion, distant metastasis and neovascularization subsequent to TAE treatment are the most severe complications observed (30). Furthermore, the development, progression, metastasis and recurrence of HCC are known to be closely associated with angiogenesis. HIF-1α is the key regulator of angiogenesis under hypoxic conditions and a useful predictor of prognosis in patients with HCC. Thus, HIF-1α is an ideal target for improving the therapeutic efficacy of TAE/TACE, and previous studies have reported that RNA interference targeting HIF-1α resulted in an ameliorative efficacy compared with that observed in the TACE group (31,32). In the present study, the lentiviral delivery (LV-H721) of the CRISPR/Cas9 protein and an HIF‑1α-specific sgRNA resulted in highly efficient HIF‑1α modification (Fig. 2C), and the suppression of VEGF and MDR1 in SMMC -7721 liver tumor cells, indicating that HIF‑1α was efficiently disrupted by the CRISPR/Cas9 system (Fig. 2D and G). These findings are consistent with the observations of previous studies on HIF-1α, where HIF-1α downregulation was reported to inhibit the expression levels of VEGF and MDR1 in cancer cells (17,33). Notably, LV-H721 infection led to HIF-1α knockout in the SMMC-7721 xenograft tissues (Fig. 2A). In addition, CoCl2 was used to mimic a hypoxic tumor microenvironment in vitro (34), and the in vitro anti-tumor effect of the HIF‑1α knockout in the SMMC-7721 cells was exhibited by the impairment of the liver cancer cell migration and invasiveness capacities, particularly under hypoxic conditions (Fig. 3). Under hypoxic conditions, HIF-1α knockout reduced cell proliferation and was accompanied by increased cell apoptosis in the SMMC-7721 cells (Fig. 4), indicating that combining the CRISPR/Cas9 system targeting HIF‑1α with TAE in the hypoxic tumor microenvironment may more efficient in HCC treatment. Notably, this combination therapy of CRISPR/Cas9-mediated HIF‑1α knockout and TAE (namely the HAL+LV-H721 treatment) conferred a more significant tumor suppressive effect and a prolonged survival time in the HCC-bearing mice (Fig. 5). Furthermore, the reduced expression of CD31 in the HAL+LV-H721 tumor tissues indicated that

Figure 6. Immunohistochemical analysis of microvascular density and TUNEL assay in the mouse orthotopic tumor model. Tumor tissues were acquired at 20 days after the different treatments. (A) Monoclonal anti-CD31 antibody staining of the section to examine the microvascular density with x20 magnification, and (B) CD31-positive cells. Five sections were counted for each slide. (C) TUNEL assay was performed on the SMMC-7721-Fluc-induced orthotopic hepatocellular carcinoma model in mice with x20 magnification, and (D) the percentage of TUNEL-positive cells is presented. Values represent the mean ± standard error of the mean, and are representative of four independent experiments. *P<0.05, **P<0.01. HAL, hepatic artery ligation; Ctrl, control; LV, lentivirus.
tumor angiogenesis was effectively inhibited by the HIF-1α knockout (Fig. 6). Thus, HIF-1α, a key regulator of angiogenesis, cell migration and cell invasiveness capacity, may be an effect therapeutic knockout target during TAE in the treatment of HCC.

The emerging CRISPR/Cas9 system has several advantages and has rapidly changed the landscape of cancer biology (35). By simply combining the expression of CRISPR/Cas9 and sgRNAs, highly efficient tumor genome engineering was achieved. Relevant research studies have reported that CRISPR/Cas9 interventions targeting hepatitis B virus (HBV) cellular genes in cancer resulted in the cleavage of the HBV genome and viral clearance in a mouse model (36,37). Nevertheless, the application of the lentiviral CRISPR/Cas9 system in clinical cases is limited by the lack of efficient delivery methods and the toxicity of the Cas9 nuclease (38). Notably, lentivirus infection and the CRISPR/Cas9 system mediating the knockout of a certain gene is permanent, and causes insertion inactivation of genes and off-target events. Therefore, the development of a delivery vector and a CRISPR/Cas9 system that mainly targets only the cancer cell genome is highly desirable.

In the current study, SMMC-7721 cells were first infected with LV-H721 lentivirus and then used to establish an HCC mouse model. However, for the combination of TAE and the lentivirus-mediated CRISPR/Cas9 system, it may be better to inject an emulsion of materials that include the LV-H721 lentivirus into the HCC feeding arteries, thereby blocking the blood supply to the tumor. Furthermore, compared with the use of an intravenous systemic injection, a more efficient HIF-1α gene knockout may be achieved by hepatic transarterial embolization with LV-H721 due to the close encounters between the lentiviruses, HCC tissues and a desirable HIF-1α target. Thus, an extension of the current study could further utilize this combination strategy in rats. Thus far, it appears that using the lentivirus-mediated CRISPR/Cas9 system to correct an error in a certain human gene or to remove an alien gene may be more practical and achievable during TAE. Further studies are required to elucidate the application of the CRISPR/Cas9 system in treating human malignancies with a lentivirus vector.

In conclusion, the present study revealed that the CRISPR/Cas9-mediated HIF-1α knockout enhanced the antitumor effect of TAE in HCC, suggesting that HIF-1α may serve as a potential clinical knockout target, in combination with TAE/TACE, for the treatment of HCC.

Acknowledgements

We are grateful to Qingshuang Zou, Jianlong Kang and Shiyou Chen for their contributions to this project. We thank Jie Zhang, Wei Ma, Yang Li, Shang Chen and Weilin Lu for their animal management and technical supports.

Funding

This study was funded by the National Natural Science Foundation of Guangdong (grant no. 2015A030310409, 2017A030313846), and the Science and Technology Innovation Foundation of Shenzhen (grant no. JCYJ20160422152408705).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

LPL and SYB conceived and designed the study; QL and DA wrote the manuscript, carried out cellular and animal-associated experiments and performed statistical analyses; DF collected the clinical samples and analyzed the clinical information; ZW, YZ and ZYD assisted with the collection of clinical tumor samples, Transwell and TUNEL staining assay; DW and YL assisted with PCR, western blotting and packaging and purification of CRISPR/Cas9 lentiviruses; RL was involved in the conception of the study; QTY was responsible for cell culture and IHC staining. All authors read and approved the manuscript and agreed to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The present study conformed to the Ethical Guidelines of the 2013 revision of the Declaration of Helsinki. All the HCC patients provided written informed consent for the use of clinical specimens for medical research. The studies using the human specimens and the mouse experiments were approved by the Ethics Committee of the Jinan University (Guangzhou, Guangdong, China). All the animal experiments were conducted with the standard guidelines for the care of animals, which were approved by the Welfare Committee of the Center of Experimental Animals (Jinan University, Guangzhou, Guangdong, China).

Patient consent for publication

All author consent to the publication of this work.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal  A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. The Lancet 379: 1245-1255, 2012.
3. Omyla-Staszewska J and Deptala A: Effective therapeutic management of hepatocellular carcinoma-on the basis of a clinical case. Contemp Oncol 16: 60-63, 2012.
4. Song DS, Nam SW, Bae SH, Kim JD, Jang JW, Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, et al: Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 21: 2395-2404, 2015.
5. Wang YX, De Baere T, Idee JM and Ballet S: Transcatheter embolization therapy in liver cancer: An update of clinical evidences. Chin J Cancer Res 27: 96-121, 2015.
6. Lo CM, Nguyen H, Tsou WK, Liu CL, Lam CM, Poon RT, Fan ST and Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
7. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G and Sood AK: RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer 11: 59-67, 2011.

8. Sharma P and Allison JP: The future of immune checkpoint therapy. Science 348: 56-61, 2015.

9. Liu Q, Yang Y, Tan X, Tao Z, Adah D, Yu S, Lu J, Zhao S, Qin L, Qin L and Chen X: Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Oncotarget 8: 24785-24796, 2017.

10. Rosenberg SA and Restifo NP: Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348: 62-68, 2015.

11. Doudna JA and Charpentier E: Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346: 1258096, 2014.

12. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas9 systems. Science 339: 819-823, 2013.

13. Eid A and Mahfouz MM: Genome editing: The road of CRISPR/Cas9 from bench to clinic. Exp Mol Med 48: e265, 2016.

14. Zucman-Rossi J, Villanueva A, Nault JC and Llovet JM: Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149: 1226-1239 e1224, 2015.

15. Favaro E, Lord S, Harris AL and Buffa FM: Gene expression and hypoxia in breast cancer. Genome Med 3: 1-12, 2011.

16. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM and Wenger RH: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220, 2003.

17. Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823, 2013.

18. Richter E, Katschinski DM and Wenger RH: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220, 2003.

19. Zhang Z: Construction and characterization of a PDCD5 recombinant lentivirus vector and its expression in tumor cells. Oncol Rep 28: 91-98, 2012.

20. Lopez-Sanchez LM, Jimenez C, Valverde A, Hernandez V, Peñarando J, Martinez A, Lopez-Pedrera C, Muñoz-Castañeda JR, De la Haba-Rodriguez JR, Aranda E, et al: CoCl2, a mimic of hypoxia, induces formation of polyplid giant cells with stem characteristics in colon cancer. PLoS One 9: e9943, 2014.

21. Zou XP: Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α pathway in vitro and in vivo. J Cell Biochem 113: 2474-2487, 2012.

22. Wu X, Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823, 2013.

23. Wang S, Zeng X, Liu Y, Liang C, Zhang H, Liu C, Du W and Zhang Z: Construction and characterization of a PDCD5 recombinant lentivirus vector and its expression in tumor cells. Oncol Rep 28: 91-98, 2012.

24. Zeng X, Liu Y, Liang C, Zhang H, Liu C, Du W and Zhang Z: Construction and characterization of a PDCD5 recombinant lentivirus vector and its expression in tumor cells. Oncol Rep 28: 91-98, 2012.

25. Lopez-Sanchez LM, Jimenez C, Valverde A, Hernandez V, Peñarando J, Martinez A, Lopez-Pedrera C, Muñoz-Castañeda JR, De la Haba-Rodriguez JR, Aranda E, et al: CoCl2, a mimic of hypoxia, induces formation of polyplid giant cells with stem characteristics in colon cancer. PLoS One 9: e9943, 2014.

26. Zou XP: Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α pathway in vitro and in vivo. J Cell Biochem 113: 2474-2487, 2012.

27. Wu X, Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823, 2013.

28. Richter E, Katschinski DM and Wenger RH: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220, 2003.

29. Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823, 2013.

30. Wang S, Zeng X, Liu Y, Liang C, Zhang H, Liu C, Du W and Zhang Z: Construction and characterization of a PDCD5 recombinant lentivirus vector and its expression in tumor cells. Oncol Rep 28: 91-98, 2012.

31. Lopez-Sanchez LM, Jimenez C, Valverde A, Hernandez V, Peñarando J, Martinez A, Lopez-Pedrera C, Muñoz-Castañeda JR, De la Haba-Rodriguez JR, Aranda E, et al: CoCl2, a mimic of hypoxia, induces formation of polyplid giant cells with stem characteristics in colon cancer. PLoS One 9: e9943, 2014.

32. Zou XP: Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α pathway in vitro and in vivo. J Cell Biochem 113: 2474-2487, 2012.

33. Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823, 2013.

34. Richter E, Katschinski DM and Wenger RH: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22: 3213-3220, 2003.

35. Sanchez-Rivera FJ and Jacks T: Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 15: 387-395, 2015.

36. Zeng X, Liu Y, Liang C, Zhang H, Liu C, Du W and Zhang Z: Construction and characterization of a PDCD5 recombinant lentivirus vector and its expression in tumor cells. Oncol Rep 28: 91-98, 2012.

37. Seeger Cand Ji AS: Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA. Mol Ther 24: 1258-1266, 2016.

38. White MK and Kamel K: CRISPR/Cas9 and cancer targets: Future possibilities and present challenges. Oncotarget 7: 12305-12317, 2016.